X-ray lightsource at DESY identifies promising candidates for COVID drugs
Electron density map of the most antiviral active ingredient calpeptin (yellow) binding at the main protease. © DESY/Sebastian Günther
At DESY's high-brilliance X-ray light source PETRA III, a team from more than 30 research institutions has identified several candidates for active substances against the coronavirus SARS-CoV-2. They bind to an important protein of the virus and could thus be the basis for a drug against Covid-19. The MX team from HZB examined part of the measurement data with special analysis algorithms in order to identify suitable active substances. The study has now been published in the renowned journal Science.
In a so-called X-ray screening, the researchers, under the leadership of DESY, tested almost 6000 known active substances that already exist for the treatment of other diseases in a short amount of time. After measuring about 7000 samples, the team was able to identify a total of 37 substances that bind to the main protease (Mpro) of the SARS-CoV-2 virus, as the scientists report online today in the journal Science. Seven of these substances inhibit the activity of the protein and thus slow down the multiplication of the virus. Two of them do this so promisingly that they are currently under further investigation in preclinical studies. This drug screening – probably the largest of its kind – also revealed a new binding site on the main protease of the virus to which drugs can couple.
“The active substances Calpeptin and Pelitinib clearly showed the highest antivirality with good cell compatibility. Our cooperation partners have therefore already started preclinical investigations with these two substances,” explains DESY researcher Sebastian Günther, first author of the Science publication.
In addition to DESY scientists, researchers from the Universities of Hamburg and Lübeck, the Bernhard Nocht Institute for Tropical Medicine, the Fraunhofer Institute for Translational Medicine and Pharmacology, the Heinrich Pette Institute, the European XFEL, the European Molecular Biology Laboratory EMBL, the Max Planck Society, the Helmholtz-Zentrum Berlin and other institutions are involved in the work.
Note: This is a shortened version of the full text of the press release published at DESY Website.
- BESSY II: New sample environment allows glimpse into thermocatalytic processesA novel measurement cell allows, for the first time, soft and hard X-ray investigations under high pressures of up to 20 bar and temperatures of up to 400°C. This provides new insights into thermocatalytic processes, such as the Fischer-Tropsch synthesis for producing synthetic fuels. The development of the measurement cell is considered a significant achievement within the Care-O-Sene project.
- Precision interface chemistry pushes perovskite solar cells beyond 26% efficiencyAn international research collaboration has developed a new molecular strategy for controlling one of the most critical interfaces in perovskite solar cells. The resulting solar cells reached a power conversion efficiency of 26.19% in the n i p architecture, together with strong operational stability under prolonged illumination and elevated temperature. The results have been published in the Journal of the American Chemical Society.
- Perovskite triple-junction solar cells: Even more efficient with GO/SAM bilayersPerovskite semiconductors efficiently convert sunlight into electrical energy; they are also inexpensive and extremely lightweight. A team at HZB has developed a triple-junction solar cell comprising different perovskite semiconductors, with a novel bilayer of graphene oxide (GO) and a self-assembled monolayer (SAM) as the hole conductor. This bilayer significantly increases both efficiency and long-term stability. The efficiency of the novel perovskite triple-junction solar cell is 27.3% and shows hardly any decline even after more than 770 hours of operation. The study has been published in the renowned journal Joule.